Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

182 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Safety of extended interval dosing immune checkpoint inhibitors: a multicenter cohort study.
Cantini L, Paoloni F, Pecci F, Spagnolo F, Genova C, Tanda ET, Aerts S, Rebuzzi SE, Fornarini G, Zoratto F, Fancelli S, Lupi A, Della Corte CM, Parisi A, Bennati C, Ortega C, Atzori F, Piovano PL, Orciuolo C, De Tursi M, Ghidini M, Botticelli A, Scagnoli S, Belluomini L, Leporati R, Veccia A, Di Giacomo AM, Festino L, Cortinovis D, Acquati M, Filetti M, Giusti R, Tucci M, Sergi MC, Garutti M, Puglisi F, Manglaviti S, Citarella F, Santoni M, Rijavec E, Lo Russo G, Santini D, Addeo A, Antonuzzo L, Indini A, Rocchi MBL, Cortellini A, Grossi F, Ascierto PA, Aerts JGJV, Berardi R. Cantini L, et al. Among authors: genova c. J Natl Cancer Inst. 2023 Jul 6;115(7):796-804. doi: 10.1093/jnci/djad061. J Natl Cancer Inst. 2023. PMID: 37042716 Free PMC article.
A miRNA Panel Predicts Sensitivity of FGFR Inhibitor in Lung Cancer Cell Lines.
Ren S, Rivard CJ, Yu H, Genova C, Rozenboom L, Gao D, Hinz TK, Rikke BA, Wynes MW, Caldwell C, Agustoni F, Kenichi Suda, Jiang T, Zhou C, Heasley LE, Hirsch FR. Ren S, et al. Among authors: genova c. Clin Lung Cancer. 2018 Sep;19(5):450-456. doi: 10.1016/j.cllc.2018.06.004. Epub 2018 Jun 28. Clin Lung Cancer. 2018. PMID: 30146263 Free PMC article.
The administration of gefitinib in patients with advanced non-small-cell lung cancer after the failure of erlotinib.
Grossi F, Rijavec E, Dal Bello MG, Defferrari C, Brianti A, Barletta G, Genova C, Murolo C, Cosso M, Fontanini G, Boldrini L, Truini M, Pronzato P. Grossi F, et al. Among authors: genova c. Cancer Chemother Pharmacol. 2012 Jun;69(6):1407-12. doi: 10.1007/s00280-012-1848-4. Epub 2012 Feb 21. Cancer Chemother Pharmacol. 2012. PMID: 22349923 Clinical Trial.
Ipilimumab (MDX-010) in the treatment of non-small cell lung cancer.
Genova C, Rijavec E, Barletta G, Sini C, Dal Bello MG, Truini M, Murolo C, Pronzato P, Grossi F. Genova C, et al. Expert Opin Biol Ther. 2012 Jul;12(7):939-48. doi: 10.1517/14712598.2012.681371. Epub 2012 Apr 16. Expert Opin Biol Ther. 2012. PMID: 22506716 Review.
Pemetrexed for the treatment of non-small cell lung cancer.
Genova C, Rijavec E, Truini A, Coco S, Sini C, Barletta G, Dal Bello MG, Alama A, Savarino G, Pronzato P, Boccardo F, Grossi F. Genova C, et al. Expert Opin Pharmacother. 2013 Aug;14(11):1545-58. doi: 10.1517/14656566.2013.802774. Epub 2013 May 17. Expert Opin Pharmacother. 2013. PMID: 23683110 Review.
Afatinib for the treatment of advanced non-small-cell lung cancer.
Genova C, Rijavec E, Barletta G, Burrafato G, Biello F, Dal Bello MG, Coco S, Truini A, Alama A, Boccardo F, Grossi F. Genova C, et al. Expert Opin Pharmacother. 2014 Apr;15(6):889-903. doi: 10.1517/14656566.2014.902445. Expert Opin Pharmacother. 2014. PMID: 24646054 Review.
182 results